Lymphocytic profiling in thyroid cancer provides clues for failure of tumor immunity

Endocrine-Related Cancer

Volumn 21, Issue 3, 2014, Pages 505-516

  Imam, Shahnawaz ^a   Paparodis, Rodis ^a,b   Sharma, Deepak ^a   Jaume, Juan Carlos ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Autoimmunity; Hashimoto thyroiditis; Thyroid cancer; Tumor immunity

Indexed keywords

INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; GAMMA INTERFERON; INTERLEUKIN 17;

ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNITY; CANCER PATIENT; CONTROLLED STUDY; HASHIMOTO DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; LYMPHOCYTE PROLIFERATION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; THYROID CANCER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; CASE CONTROL STUDY; CELL CULTURE; COMPARATIVE STUDY; FLOW CYTOMETRY; IMMUNOLOGY; LYMPHOCYTE; METABOLISM; PAPILLARY CARCINOMA; PATHOLOGY; THYROID GLAND; THYROID TUMOR;

AUTOIMMUNITY; CARCINOMA, PAPILLARY; CASE-CONTROL STUDIES; CELLS, CULTURED; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HASHIMOTO DISEASE; HUMANS; IMMUNE TOLERANCE; INTERFERON-GAMMA; INTERLEUKIN-17; LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; THYROID GLAND; THYROID NEOPLASMS;

EID: 84903581399     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-13-0436     Document Type: Article

References (43)

1. Abbas AK, Benoist C, Bluestone JA, Campbell DJ, Ghosh S, Hori S, Jiang S, Kuchroo VK, Mathis D, Roncarolo MG et al. 2013 Regulatory T cells: recommendations to simplify the nomenclature. Nature Immunology 14 307-308. (doi:10.1038/ni.2554)
2. Arscott PL, Stokes T, Myc A, Giordano TJ, ThompsonNW& Baker JR Jr 1999 Fas (CD95) expression is up-regulated on papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 84 4246-4252. (doi:10.1210/jcem.84.11.6139) (Pubitemid 30644225)
3. Baecher-Allan C & Anderson DE 2006 Regulatory cells and human cancer. Seminars in Cancer Biology 16 98-105. (doi:10.1016/j.semcancer.2005.11.003) (Pubitemid 43172058)
4. Balkwill F, Charles KA & Mantovani A 2005 Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7 211-217. (doi:10.1016/j.ccr.2005.02.013) (Pubitemid 40568680)
5. Basolo F,Giannini R, Faviana P, Fontanini G, Patricelli-Malizia A, Ugolini C, Elisei R, Miccoli P & Toniolo A 2004 Thyroid papillary carcinoma: preliminary evidence for a germ-line single nucleotide polymorphism in the Fas gene. Journal of Endocrinology 182 479-484. (doi:10.1677/joe.0.1820479) (Pubitemid 39276215)
6. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, Kelly TE, Saulsbury FT, Chance PF & Ochs HD 2001 The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nature Genetics 27 20-21. (doi:10.1038/83713) (Pubitemid 32044513)
7. Cerutti E, Campagnoli MF, Ferretti M, Garelli E, Crescenzio N, Rosolen A, Chiocchetti A, Lenardo MJ, Ramenghi U & Dianzani U 2007 Co-inherited mutations of Fas and caspase-10 in development of the autoimmune lymphoproliferative syndrome. BMC Immunology 8 28. (doi:10.1186/1471-2172-8-28)
8. Chang CC, Ciubotariu R, Manavalan JS, Yuan J, Colovai AI, Piazza F, Lederman S, Colonna M, Cortesini R, Dalla-Favera R et al. 2002 Tolerization of dendritic cells by TS cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nature Immunology 3 237-243. (doi:10.1038/ni760) (Pubitemid 34218114)
9. Chen H, Schneider D, Mazeh H, Jaume JC & Lubner S 2013 Endocrine cancer. In Abeloff's Clinical Oncology, 5th edn. pp. 1112-1142. Eds MD Abeloff, JO Armitage, JE Niederhuber, MB Kastan & WG McKenna. Philadelphia: Churchill Livingstone Elsevier.
10. Cowley SC, Meierovics AI, Frelinger JA, Iwakura Y & Elkins KL 2010 Lung CD4-CD8-double negative T cells are prominent producers of IL-17A and IFN-γ during primary respiratory murine infection with Francisella tularensis live vaccine strain. Journal of Immunology 184 5791-5801. (doi:10.4049/jimmunol.1000362)
11. DiSanto JP, Klein JS & Flomenberg N 1989 Phosphorylation and downregulation of CD4 and CD8 in human CTLs and mouse L cells. Immunogenetics 30 494-501. (doi:10.1007/BF02421181) (Pubitemid 20004220)
12. Faria AM & Weiner HL 2006 Oral tolerance and TGF-b-producing cells. Inflammation & Allergy Drug Targets 5 179-190. (doi:10.2174/ 187152806778256034)
13. Fisher GH, Rosenberg FH, Straus SE, Dale JK, Middleton LA, Lin AY, Strober W, Lenardo MJ & Puck JM 1995 Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81 935-946. (doi:10.1016/0092-8674(95)90013-6)
14. Fleisher TA 2008 The autoimmune lymphoproliferative syndrome: an experiment of nature involving lymphocyte apoptosis. Immunologic Research 40 87-92. (doi:10.1007/s12026-007-8001-1) (Pubitemid 351378035)
15. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A et al. 2006 Prognostic significance of autoimmunity during treatment of melanoma with interferon. New England Journal of Medicine 354 709-718. (doi:10.1056/ NEJMoa053007) (Pubitemid 43247141)
16. Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE & Roncarolo MG 1997 A CD4CT-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389 737-742.(doi:10.1038/39614)
17. Jaume JC 2011 Endocrine autoimmunity. In Greenspans' Basic and Clinical Endocrinology, 9th edn, pp 27-46. Eds GC Gardner & DM Shoback. New York: McGraw-Hill Medical.
18. Jin YJ, Zhang X, Boursiquot JG & Burakoff SJ 2004 CD4 phosphorylation partially reverses Nef down-regulation of CD4. Journal of Immunology 173 5495-5500. (doi:10.4049/jimmunol.173.9.5495) (Pubitemid 39392134)
19. Korman A, Yellin M & Keler T 2005 Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies. Current Opinion in Investigational Drugs 6 582-591. (Pubitemid 40852291)
20. Kriegel MA, Lohmann T, Gabler C, Blank N, Kalden JR & Lorenz HM 2004 Defective suppressor function of human CD4+ CD25+ regulatory T cells in autoimmune polyglandular syndrome type II. Journal of Experimental Medicine 199 1285-1291. (doi:10.1084/jem.20032158) (Pubitemid 38620265)
21. Marlies A, Udo G, Juergen B, Bernd S, Herrmann M & Haas JP 2007 The expanded double negative T cell populations of a patient with ALPS are not clonally related to CD4C or to CD8+T cells. Autoimmunity 40 299-301. (doi:10.1080/08916930701356473) (Pubitemid 46845525)
22. Mellman I, Coukos G & Dranoff G 2011 Cancer immunotherapy comes of age. Nature 480 480-489. (doi:10.1038/nature10673)
23. Merims S, Li X, Joe B, Dokouhaki P, Han M, Childs RW, Wang ZY, Gupta V, Minden MD & Zhang L 2011 Anti-leukemia effect of ex vivo expanded DNT cells fromAML patients: a potential novel autologous T-cell adoptive immunotherapy. Leukemia 25 1415-1422. (doi:10.1038/leu.2011.99)
24. Mirocha S, Elagin RB, Salamat S & Jaume JC 2009 T regulatory cells distinguish two types of primary hypophysitis. Clinical Experimental Immunology 155 403-411. (doi:10.1111/j.1365-2249.2008.03828.x)
25. Mitsiades N, Poulaki V, Mastorakos G, Tseleni-Balafouta ST, Kotoula V, KoutrasD&TsokosM1999 Fas ligand expression in thyroid carcinomas: a potential mechanism of immune evasion. Journal of Clinical Endocrinology and Metabolism 84 2924-2932. (doi:10.1210/jcem.84.8.5917) (Pubitemid 30642031)
26. Mitsiades N, Poulaki V, Tseleni-Balafouta S, Koutras DA & Stamenkovic I 2000 Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Research 60 4122-4129. (Pubitemid 30636594)
27. Mitsiades CS, Poulaki V, Fanourakis G, Sozopoulos E, McMillin D, Wen Z, Voutsinas G, Tseleni-Balafouta S & Mitsiades N 2006a Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation. Clinical Cancer Research 12 3705-3712. (doi:10.1158/1078-0432.CCR-05-2493) (Pubitemid 44000250)
28. Mitsiades N, Poulaki V, Tseleni-Balafouta S, Koutras DA & Stamenkovic I 2006b Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Research 60 4122-4129.
29. Mohamood AS, Bargatze D, Xiao Z, Jie C, Yagita H, Ruben D, Watson J, Chakravarti S, Schneck JP & Hamad AR 2008 Fas-mediated apoptosis regulates the composition of peripheral ab T cell repertoire by constitutively purging out double negative T cells. PLoS ONE 3 e3465. (doi:10.1371/journal.pone.0003465)
30. Paparodis R, Imam S, Todorova-Koteva K, Staii A & Jaume JC 2014 Hashimoto thyroiditis pathology and risk for thyroid cancer. Thyroid (published online ahead of print). (doi:10.1089/thy.2013.0588)
31. Poppema S, Maggio E& van den Berg A 2004 Development of lymphoma in autoimmune lymphoproliferative syndrome (ALPS) and its relationship to Fas gene mutations. Leukemia & Lymphoma 45 423-431. (doi:10.1080/ 10428190310001593166) (Pubitemid 38196023)
32. Prehn RT & Main JM 1957 Immunity to methylcholanthrene-induced sarcomas. Journal of the National Cancer Institute 18 769-778.
33. Romero P, Dunbar PR, Valmori D, Pittet M, Ogg GS, Rimoldi D, Chen JL, Liénard D, Cerottini JC & Cerundolo V 1998 Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex etramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. Journal of Experimental Medicine 188 1641-1650. (doi:10.1084/jem.188.9.1641)
34. Sakaguchi S 2000 Regulatory T cells: key controllers of immunologic self-tolerance. Cell 101 455-458. (doi:10.1016/S0092-8674(00) 80856-9)
35. Schreiber RD, Old LJ & SmythMJ 2011 Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331 1565-1570. (doi:10.1126/science.1203486)
36. Shirai T, Abe M, Yagita H, Okumura K, Morse HC III & Davidson WF 1990 The expanded populations of CD4+CD8+ T cell receptor α/βCT cells associated with the lpr and gld mutations are CD2. Journal of Immunology 144 3756-3761. (Pubitemid 20171182)
37. Teachey DT, Manno CS, Axsom KM, Andrews T, Choi JK, Greenbaum BH, McMann JM, Sullivan KE, Travis SF & Grupp SA 2005 Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS). Blood 105 2443-2448. (doi:10.1182/blood-2004-09-3542) (Pubitemid 40387044)
38. Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME & Houghton AN 2004 Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. Journal of Experimental Medicine 200 771-782. (doi:10.1084/jem.20041130) (Pubitemid 39299463)
39. Valmori D, Scheibenbogen C, Dutoit V, Nagorsen D, Asemissen AM, Rubio-Godoy V, Rimoldi D, Guillaume P, Romero P, Schadendorf D et al. 2002 Circulating tumor-reactive CD8+ T cells in melanoma patients contain a CD45RA+CCR7-effector subset exerting ex vivo tumor-specific cytolytic activity. Cancer Research 62 1743-1750. (Pubitemid 34408497)
40. Watanabe D, Suda T, Hashimoto H & Nagata S 1995 Constitutive activation of the Fas ligand gene in mouse lymphoproliferative disorders. EMBO Journal 14 12-18.
41. Wherry EJ 2011 T cell exhaustion. Nature Immunology 12 492-499. (doi:10.1038/ni.2035)
42. Wildin RS, Ramsdell F, Peake J, Faravelli F, Casanova JL, Buist N, Levy-Lahad E, Mazzella M, Goulet O & Perroni L 2001 X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nature Genetics 27 18-20. (doi:10.1038/83707) (Pubitemid 32044512)
43. Zhang ZX, Yang L, Young KJ, DuTemple B & Zhang L 2006 Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression. Nature Medicine 6 782-789. (doi:10.1038/77513)